Jerel Davis sold TSBX

August 8, 2025 · Form 4 insider transaction

Jerel Davis sold 274,990 shares of Turnstone Biologics Holdings Inc, a transaction worth N/A. The trade was recorded as u and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Disposed (sell-side)
Shares
274,990
Price
N/A
Total value
N/A
RoleDirector
SecurityCommon Stock
Transaction codeU: U
Transaction dateAugust 8, 2025
Filing dateAugust 8, 2025
Shares owned after0
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.; Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

View the original Form 4 on SEC EDGAR